Patent: 9,296,815
✉ Email this page to a colleague
Summary for Patent: 9,296,815
Title: | Antibodies with enhanced or suppressed effector function |
Abstract: | Rationally designed antibodies and polypeptides that comprise multiple Fc region amino acid substitutions that synergistically provide enhanced selectivity and binding affinity to a target Fc receptor are provided. The polypeptides are mutated at multiple positions to make them more effective when incorporated in antibody therapeutics than those having wild-type Fc components. |
Inventor(s): | D\'Angelo; Igor (Port Moody, CA), Bleile; Dustin (Vancouver, CA), Tom-Yew; Stacey A. L. (New Westminster, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula I. (Vancouver, CA), Ohrn; Anders (Vancouver, CA), Poon; David K. Y. (Richmond, CA), Dixit; Surjit B. (Richmond, CA) |
Assignee: | Zymeworks Inc. (Vancouver, British Columbia, CA) |
Application Number: | 13/638,362 |
Patent Claims: | see list of patent claims |
Details for Patent 9,296,815
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2030-03-29 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2030-03-29 |
Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | 12/10/1997 | ⤷ Try a Trial | 2030-03-29 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2030-03-29 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2030-03-29 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |